Skip to main content
Project

Identification of the genetic basis of post-infectious bronchiolitis obliterans in children
 

Argentina
Project ID
110209
Total Funding
CAD 1,000,000.00
IDRC Officer
Fabiano Santos
Project Status
Active
Duration
48 months

Programs and partnerships

Lead institution(s)

Summary

Post-infectious bronchiolitis obliterans (PIBO) is a rare but severe complication of respiratory infections caused by usually benign viruses such as adenoviruses.Read more

Post-infectious bronchiolitis obliterans (PIBO) is a rare but severe complication of respiratory infections caused by usually benign viruses such as adenoviruses. It is characterized by inflammation and scarring of the small airways in the lungs, leading to chronic breathing problems in children that continue into adulthood. It is unclear why few children develop PIBO while most recover. Differences in genes may explain why some children develop PIBO and others do not. When examining patient populations around the world, PIBO seems to be more common in the Southern hemisphere and it is more frequent in Indigenous populations than in populations of European origin who live in the same areas. While it happens in other countries, more cases have been found in Argentina, Chile and Brazil. This project proposes to uncover the genetic basis of this condition by using a combination of genetic sequencing and disease modelling among patients with PIBO recruited in a network of hospital centres across South America, Israel and Canada.

This project was selected for funding during the second research competition of the Joint Canada-Israel Health Research Program – Phase II (Communicable Diseases). The program is a partnership between IDRC, the Canadian Institutes of Health Research, the Israel Science Foundation and the Azrieli Foundation.

About the partnership

Partnership(s)

Joint Canada-Israel Health Research Program

Canada’s International Development Research Centre, in partnership with the Azrieli Foundation, the Canadian Institutes of Health Research (CIHR) and the Israel Science Foundation (ISF), is supporting cutting-edge biomedical and global health research.